6. Receptor Tyrosine Kinases and the Ras/MAPK Signaling Pathway

Overview of Receptor Tyrosine Kinases (RTKs)

Receptor Tyrosine Kinases (RTKs) represent a major class of cell-surface receptors. This academic overview covers their foundation, structural characteristics, and their pivotal role in cellular processes, including gene-to-protein regulation, protein targeting/sorting, and vesicular transport. RTKs are central to cell signaling mechanisms that govern the cytoskeleton, molecular motors (microtubules), and the cell cycle (encompassing mitosis and meiosis). Furthermore, RTKs play critical roles in specialized areas of biology such as stem cell regulation, cell death (apoptosis), and the progression of cancer.

From a structural and physiological perspective, RTKs are integral to:

• Membrane structure and transport.

• The function of $ATP$ synthase.

• Specific signaling cascades initiated by growth factors.

• Mechanisms of the Ras/MAPK pathway.

RTK Structure and Activation Mechanisms

RTKs generally exist as monomeric membrane proteins that require specific ligands to initiate activation. However, structural variations and exceptions exist within different families.

Key Ligands for RTKs

Ligands are extracellular signaling molecules (often growth factors) that bind to the extracellular domain of the RTK. Key families include:

• Nerve Growth Factor (NGF)

• Platelet-Derived Growth Factor (PDGF)

• Fibroblast Growth Factor (FGF)

• Epidermal Growth Factor (EGF)

Activation via Ligand Binding

The primary mechanism of RTK activation is ligand-induced dimerization. When a ligand binds to the extracellular domain, it induces a conformational change that allows two receptor monomers to come together. This proximity allows the intracellular kinase domains to cross-phosphorylate (autophosphorylate) tyrosine residues on their C-terminal tails.

The Insulin Receptor Exception

Unlike most RTKs that are monomers until ligand binding, the Insulin Receptor exists as a pre-formed dimer even in the absence of insulin.

• Structure: It consists of two $\alpha$ and two $\beta$ subunits held together by disulfide bonds ($S-S$).

• Activation: In the absence of insulin, the receptor is in a "Kinase inactive inverted U-shaped dimer." Upon insulin binding to the extracellular $\alpha$ subunits, the receptor undergoes a conformational change into a "Kinase active T-shaped dimer," activating the intracellular tyrosine kinase domains on the $\beta$ subunits.

The Human EGF Receptor (HER) Family

In humans, the Epidermal Growth Factor (EGF) receptors are referred to as the HER family. There are four distinct receptors: HER1, HER2, HER3, and HER4.

Ligand Specificity and Receptor Pairing

• HER1 (EGFR): Recognizes ligands such as EGF, Transforming Growth Factor $\alpha$ ($TGF-\alpha$), amphiregulin (AREG), epiregulin (EREG), epigen (EPGN), betacellulin (BTC), and HB-EGF.

• HER2: Unique because it has no known ligands. It functions as a "universal partner," forming heterodimers with HER1, HER3, or HER4. It is often already in a conformation that is "ready" for dimerization.

• HER3: Recognizes heregulin or neuregulin. It is distinct because it lacks a fully functional kinase domain (often considered a pseudo-kinase) and requires a partner for signaling.

• HER4: Recognizes heregulin, neuregulin, betacellulin, epiregulin, and HB-EGF.

Clinical Significance: HER2 in Cancer

HER2 is frequently overexpressed in aggressive forms of breast cancer. In HER2-positive breast cancer, the excessive density of receptors leads to spontaneous dimerization and over-active signaling, promoting uncontrolled cell proliferation. Evolving treatment strategies focus on inhibiting the extracellular dimerization arm or blocking the intracellular Tyrosine Kinase (TK) domain to stop the signaling cascade.

The Ras/MAPK Signaling Pathway

RTKs regulate diverse pathways, with the Ras/MAPK cascade being one of the most critical for growth and differentiation. This pathway acts as a relay, transmitting the signal from the plasma membrane to the nucleus.

Step 1: Recruitment of Adapter Proteins and GEFs

Upon RTK autophosphorylation, the phosphorylated tyrosine residues serve as docking sites for proteins with SH2 domains.

1. GRB2: An adapter protein containing one SH2 domain (binds the RTK) and two SH3 domains.

2. Sos (Son of Sevenless): Recruited by the SH3 domains of GRB2. Sos acts as a Guanine Nucleotide Exchange Factor (GEF).

Step 2: Ras Activation

Ras is a monomeric GTPase anchored to the plasma membrane.

• Inactive State: Ras is bound to $GDP$.

• Activation: Sos (the GEF) promotes the exchange of $GDP$ for $GTP$ on Ras.

• Active State: Ras bound to $GTP$ triggers the downstream kinase cascade.

• Note on Mutation: A specific mutation, Ras (G12V), renders the protein unable to hydrolyze $GTP$ back to $GDP$ ($ext{Ras-GTP} \rightarrow ext{Ras-GDP} + P_i$). This causes Ras to remain constitutively active, leading to permanent signaling and potential oncogenesis.

Step 3: The Raf/MEK/MAPK Cascade

Active Ras targets and activates a series of kinases:

1. Raf (MAPKKK): Inactive Raf is sequestered in the cytosol by the 14-3-3 protein and its own N-terminal autoinhibitory domain. Ras-GTP recruits Raf to the membrane, leading to its activation.

2. MEK (MAPKK): Raf phosphorylates and activates MEK.

3. MAP Kinase (MAPK/ERK): MEK phosphorylates MAPK on both threonine and tyrosine residues ($T$ and $Y$), making it active.

Nuclear Translocation and Gene Expression

Active, dimeric MAP kinase translocates from the cytosol into the nucleus to regulate gene expression.

1. Phosphorylation of Substrates:    - MAPK phosphorylates terrestrial transcription factors like TCF.    - MAPK also phosphorylates $p90^{RSK}$ in the cytosol, which then enters the nucleus and phosphorylates SRF (Serum Response Factor).

2. Binding the SRE: The phosphorylated TCF and SRF bind to the Serum Response Element (SRE), a promoter sequence for early-response genes.

3. Transcription of c-fos: The activation of the SRE leads to the transcription of the $c-fos$ gene, which is essential for initiating the cell cycle and developmental processes.

Termination and Feedback Inhibition

Cells employ several mechanisms to "turn off" the RTK/MAPK pathway to prevent aberrant signaling:

• Feedback Inhibition: Active MAPK can phosphorylate and inhibit the upstream HER1 receptor, reducing the initial signal input.

• DUSP (Dual Specificity Phosphatases): Enzymes such as DUSP6 and DUSP7 dephosphorylate the critical Threonine ($T$) and Tyrosine ($Y$) residues on MAPK, returning it to an inactive state.

• Ras-GAP: Ras-GTPase Activating Proteins (GAPs) accelerate the intrinsic activity of Ras to hydrolyze $GTP$ into $GDP$, thereby inactivating the monomeric GTPase.

Questions & Discussion

Q: How does ligand binding bring the receptor together? A: Ligand binding to the extracellular domain causes a conformational change that exposes a "dimerization arm" (especially in the HER family), promoting physical interaction between two receptor subunits.

Q: What is distinct about HER-3 and HER-2? A: HER-2 has no known ligand and is always in an "active" conformation ready to dimerize. HER-3 has no (or very weak) kinase activity and must signal through heterodimerization with other family members.

Q: Is Sos a GEF or GAP? A: Sos is a GEF (Guanine Nucleotide Exchange Factor), as it facilitates the exchange of $GDP$ for $GTP$.

Q: What happens when a Ras (G12V) mutation renders the protein unable to hydrolyze GTP? A: The protein remains stuck in the "on" (GTP-bound) state indefinitely. This leads to continuous, uncontrolled signaling through the Raf/MEK/MAPK pathway, even in the absence of external growth factors, which is a hallmark of cancer cell behavior.

Q: How might active MAPK function? A: Active MAPK typically dimerizes and translocates to the nucleus where it phosphorylates transcription factors to change the cell's gene expression profile, specifically targeting genes for growth and division.